SCHEMBL3624124

SCHEMBL3624124

CC(C)Nc1ccc2c(c1)COC2=O

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.55
KDM4E B2RXH2 2/20 0.55
ALDH1A1 P00352 4/20 0.53
LMNA P02545 2/20 0.51
GAA P10253 1/20 0.51
HSD17B10 Q99714 1/20 0.50
PKM P14618 2/20 0.49
NPC1 O15118 1/20 0.48
NR3C1 P04150 1/20 0.47
PGR P06401 1/20 0.47
NR3C2 P08235 1/20 0.47
PRF1 P14222 2/20 0.46
RECQL P46063 1/20 0.46
PRMT3 O60678 1/20 0.46
POLB P06746 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
MAOA P21397 1/20 0.46
MAOB P27338 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5764438 0.79 MAPT (0.68) MAPTKDM4EALDH1A1GAAHSD17B10
SCHEMBL5558567 0.78 MAPT (0.61) MAPTKDM4EALDH1A1LMNAGAA
SCHEMBL5365075 0.76 PRF1 (0.68) MAPTKDM4EALDH1A1LMNAGAA
SCHEMBL13797360 0.75 MAPT (0.56) MAPTKDM4EALDH1A1LMNAGAA
SCHEMBL29606212 0.74 MAPT (0.66) MAPTKDM4EALDH1A1LMNAGAA
SCHEMBL14157497 0.73 MAPT (0.66) MAPTKDM4EALDH1A1GAAHSD17B10
SCHEMBL7970252 0.73 NPC1 (0.53) MAPTKDM4EALDH1A1LMNAGAA
SCHEMBL25266820 0.72 MAPT (0.57) MAPTKDM4EALDH1A1LMNAGAA
SCHEMBL25213620 0.72 MAPT (0.57) MAPTKDM4EALDH1A1LMNAGAA
SCHEMBL29450168 0.72 MAPT (0.57) MAPTKDM4EALDH1A1LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7652006-B2 For therapy and prophylaxis of neuronal loss associated with stroke, global and focal ischemia, CNS trauma, hypoglycemia and surgery, for ameliorating neurodegenerative diseases EURO-CELTIQUE S.A. (LU) 2010-01-26 US disclosed
US-20040162299-A1 Substituted quinazolines and analogs and the use thereof EURO-CELTIQUE, S.A. 2004-08-19 US disclosed
EP-1066039-A4 SUBSTITUTED QUINAZOLINES AND ANALOGS AND THE USE THEREOF COCENSYS INC (US) 2003-02-26 EP disclosed
US-20030033089-A1 Substituted quinazolines and analogs and the use thereof EURO-CELTIQUE S.A. 2003-02-13 US disclosed
US-6465472-B1 SUCH AS 1-(2-DIETHYLAMINOETHYL)-6,7-METHYLENEDIOXY-4-(3,4-METHYLENE -DIOXYPHENYL)QUINAZOLIN-2(1H)-ONE; AMPA IONOTROPIC RECEPTOR ANTAGONISTS; ANTICONVULSANTS, COGNITIVE ENHANCERS, PREVENTION OF NEURODEGENERATION EURO-CELTIQUE S.A. (LU) 2002-10-15 US disclosed
EP-1066039-A1 SUBSTITUTED QUINAZOLINES AND ANALOGS AND THE USE THEREOF Cocensys, Inc. (US) 2001-01-10 EP disclosed
WO-1999044612-A1 SUBSTITUTED QUINAZOLINES AND ANALOGS AND THE USE THEREOF COCENSYS, INC. (US) 1999-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162299-A1 Substituted quinazolines and analogs and the use thereof CHRNA7, CHRNA2, CHRNA10 MAPT 170/4885KDM4E 2596/4885ALDH1A1 1819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.